Dr. Katharine Hsu, an esteemed physician-scientist who specializes in immunology research and treatment of blood cancers, has been named director of the Tri-Institutional M.D.-Ph.D. Program, a joint program between Weill Cornell Medicine, The Rockefeller University and Memorial Sloan Kettering Cancer Center.
Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.
